Daily Sepsis Research Analysis
A multicenter prospective study validated a high-sensitivity droplet digital PCR panel for rapid Gram-negative bloodstream infection diagnosis, potentially transforming early sepsis management. Mechanistic work uncovered SIRT2-controlled succinylation of SERCA2a (K352) as a pathway driving sepsis-induced cardiac dysfunction. Updated Japanese sepsis guidelines (J-SSCG 2024) deliver 42 GRADE-based recommendations across diagnosis, resuscitation, antimicrobials, and adjunctive care.
Summary
A multicenter prospective study validated a high-sensitivity droplet digital PCR panel for rapid Gram-negative bloodstream infection diagnosis, potentially transforming early sepsis management. Mechanistic work uncovered SIRT2-controlled succinylation of SERCA2a (K352) as a pathway driving sepsis-induced cardiac dysfunction. Updated Japanese sepsis guidelines (J-SSCG 2024) deliver 42 GRADE-based recommendations across diagnosis, resuscitation, antimicrobials, and adjunctive care.
Research Themes
- Rapid molecular diagnostics for bloodstream infection in sepsis
- Mechanisms of sepsis-induced cardiomyopathy
- Evidence-based guideline updates for sepsis management
Selected Articles
1. Performance of ddPCR-GNB for microbial diagnosis of suspected bloodstream infection due to the four most common gram-negative bacteria: a prospective, multicenter study.
In 1,041 prospectively enrolled patients with suspected BSI, a plasma ddPCR panel for four common Gram-negative pathogens achieved 98.5% sensitivity, 72.8% specificity, and 99.9% negative predictive value, detecting positives in 31.7% vs 6.3% by culture. Discordant ddPCR-positive/culture-negative cases were frequent, underscoring enhanced detection compared with culture.
Impact: This is the first multicenter validation of ddPCR for bloodstream infection, demonstrating near-perfect rule-out capability and substantially higher detection than blood culture.
Clinical Implications: High sensitivity and negative predictive value suggest ddPCR could accelerate pathogen identification and enable earlier optimization or de-escalation of antibiotics in suspected sepsis, though strategies to manage ddPCR-positive/culture-negative results and antimicrobial stewardship protocols are needed.
Key Findings
- ddPCR-GNB detected target Gram-negative pathogens in 31.7% vs 6.3% by blood culture.
- Sensitivity 98.5% (95% CI 91.9–99.9), specificity 72.8% (95% CI 69.9–75.5), and NPV 99.9% (95% CI 99.2–100).
- There were 265 ddPCR-positive/culture-negative discordant cases and one culture-positive/ddPCR-negative case.
- First multicenter clinical validation of ddPCR for etiologic diagnosis of bloodstream infection.
Methodological Strengths
- Prospective multicenter enrollment with large sample size (n=1,041).
- Discordant results adjudicated using additional microbiology and clinical evidence.
Limitations
- Specificity was moderate and many ddPCR-positive/culture-negative cases raise concerns about clinical interpretation.
- Turnaround time, outcome impact, and cost-effectiveness were not reported.
Future Directions: Embed ddPCR into sepsis bundles to test effects on time-to-appropriate therapy and outcomes; refine panels/thresholds to reduce false positives; evaluate stewardship algorithms for discordant results.
UNLABELLED: We aimed to validate the performance of ddPCR-GNB, a plasma droplet digital PCR panel targeting the four most common gram-negative bacteria, for patients with suspected bloodstream infection (BSI). Patients suspected of having BSIs were prospectively enrolled. The results of blood culture and ddPCR-GNB were compared, and cases with discordant results were arbitrated on the basis of additional microbiological results and clinical evidence. A total of 1,041 patients were enrolled. Blood culture and ddPCR-GNB results were positive for targeted bacteria in 6.3% and 31.7% of patients, respectively. The overall per-patient sensitivity and specificity of ddPCR-GNB for proven BSIs were 98.5% (95% CI, 91.9% to 99.9%) and 72.8% (95% CI, 69.9% to 75.5%), respectively; the negative predictive value was 99.9% (95% CI, 99.2% to 100%). The discordant results included 265 cases (25.5%) with negative companion blood culture results but positive ddPCR-GNB results and one case vice versa. A total of 23.7% of the cases were attributed to probable ( IMPORTANCE: This is the first multicentral study to validate the clinical performance of ddPCR in etiological diagnosis of bloodstream infection. The results showed that ddPCR has high sensitivity and increased detection rate compared with blood culture. The study proved the potential of the ddPCR method in microbial diagnoses.
2. Succinylation of SERCA2a at K352 Promotes Its Ubiquitinoylation and Degradation by Proteasomes in Sepsis-Induced Heart Dysfunction.
Systems-level succinylome profiling identified hypersuccinylation of SERCA2a in sepsis, with K352 succinylation promoting K48-linked ubiquitination, proteasomal degradation, and reduced activity. SIRT2 interacts with SERCA2a and decreases K352 succinylation, highlighting a targetable axis in sepsis-induced cardiac dysfunction.
Impact: This work elucidates a previously unrecognized post-translational mechanism driving sepsis cardiomyopathy and nominates SIRT2–SERCA2a succinylation as a therapeutic target.
Clinical Implications: Although preclinical, targeting SIRT2 or preventing SERCA2a K352 succinylation could preserve calcium handling and myocardial function in sepsis; translational studies and pharmacologic modulation are warranted.
Key Findings
- Identified 10,324 lysine succinylation sites in heart tissue; 1,042 were differentially regulated by LPS.
- SERCA2a was hypersuccinylated in septic rat myocardium and LPS-treated cardiomyocytes.
- K352 succinylation promoted K48-linked ubiquitination and proteasomal degradation of SERCA2a, decreasing its level and activity.
- SIRT2 interacted with SERCA2a and reduced K352 succinylation, acting as a desuccinylase candidate.
Methodological Strengths
- Comprehensive succinylome profiling combined with functional validation of a specific lysine site (K352).
- Multi-modal evidence (co-IP, LC–MS/MS, in vivo septic rats and in vitro LPS-treated cardiomyocytes).
Limitations
- Preclinical study without human myocardial validation or clinical outcome data.
- Therapeutic modulation of SIRT2–SERCA2a axis was not tested in vivo.
Future Directions: Validate SERCA2a K352 succinylation and SIRT2 activity in human sepsis myocardium; test pharmacologic SIRT2 modulators and gene strategies to preserve SERCA2a; assess cardiac function and survival in sepsis models.
BACKGROUND: Intracellular Ca METHODS: We conducted a succinylome profiling and developed a protein language model-based framework to prioritize succinylation at a functionally important site, and further analysis revealed crosstalk between ubiquitination and succinylation of SERCA2a. The succinylation of SERCA2a in septic rats or lipopolysaccharide-treated cells were detected by co-immunoprecipitation. Thereafter, a desuccinylated SERCA2a RESULTS: We identified 10 324 succinylated lysine sites in heart tissues, including 1042 differentially succinylated lysine sites, in response to lipopolysaccharide. SERCA2a was hypersuccinylated in the myocardial tissues of septic rats and lipopolysaccharide-treated cardiomyocytes. Increased ubiquitination level, reduced protein level, and activity of SERCA2a were observed, along with increased succinylation of SERCA2a in vivo and in vitro. K352 was essential for SERCA2a succinylation, which reduced SERCA2a protein level by promoting formation of the K48 ubiquitin chain on SERCA2a and its degradation by proteasomes. Co-immunoprecipitation combined with liquid chromatography-tandem mass spectrometry identified that SIRT2 (sirtuin2), a deacylase, exhibited interaction with SERCA2a. Furthermore, SIRT2 decreased K352 succinylation of SERCA2a, suggesting that SIRT2 may function as a desuccinylase for SERCA2a. CONCLUSIONS: Succinylation of SERCA2a at K352, which was controlled by SIRT2, promotes its ubiquitinoylation and degradation by proteasomes in sepsis-induced heart dysfunction.
3. The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2024.
J-SSCG 2024 provides structured, GRADE-based guidance across nine domains of sepsis care, producing 42 recommendations, 7 good practice statements, and 22 background items via a modified Delphi process. The guideline aims to standardize initial management through post-ICU recovery across multidisciplinary teams.
Impact: A comprehensive national guideline shapes clinical practice across the care continuum and identifies priority research areas in sepsis management.
Clinical Implications: The guideline supports standardized diagnostic criteria, antimicrobial stewardship, hemodynamic resuscitation strategies, and adjunctive therapies, facilitating consistent care pathways and quality improvement.
Key Findings
- Covers nine domains including diagnosis/source control, antimicrobials, initial resuscitation, blood purification, DIC, adjunctive therapy, PICS, patient/family care, and pediatrics.
- Addresses 78 clinical issues with 42 GRADE-based recommendations, 7 good practice statements, and 22 background questions.
- Recommendations were formulated via GRADE and finalized using a modified Delphi voting process by all committee members.
Methodological Strengths
- Use of GRADE framework ensures transparent linkage of evidence to recommendations.
- Modified Delphi consensus across multidisciplinary committee enhances applicability.
Limitations
- Guidelines synthesize existing evidence and may reflect national practice contexts; not primary outcome studies.
- Heterogeneous evidence quality across topics limits the strength of some recommendations.
Future Directions: Prospective implementation studies to evaluate adherence and outcomes; targeted RCTs addressing highlighted research questions; alignment and comparison with international guidelines to harmonize best practices.
The 2024 revised edition of the Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock (J-SSCG 2024) is published by the Japanese Society of Intensive Care Medicine and the Japanese Association for Acute Medicine. This is the fourth revision since the first edition was published in 2012. The purpose of the guidelines is to assist healthcare providers in making appropriate decisions in the treatment of sepsis and septic shock, leading to improved patient outcomes. We aimed to create guidelines that are easy to understand and use for physicians who recognize sepsis and provide initial management, specialized physicians who take over the treatment, and multidisciplinary healthcare providers, including nurses, physical therapists, clinical engineers, and pharmacists. The J-SSCG 2024 covers the following nine areas: diagnosis of sepsis and source control, antimicrobial therapy, initial resuscitation, blood purification, disseminated intravascular coagulation, adjunctive therapy, post-intensive care syndrome, patient and family care, and pediatrics. In these areas, we extracted 78 important clinical issues. The GRADE (Grading of Recommendations Assessment, Development and Evaluation) method was adopted for making recommendations, and the modified Delphi method was used to determine recommendations by voting from all committee members. As a result, 42 GRADE-based recommendations, 7 good practice statements, and 22 information-to-background questions were created as responses to clinical questions. We also described 12 future research questions.